Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1004 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti² and Augustine Manadan³, ¹John H Stroger Hospital of Cook County, Riverside, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
Abstract Number: 1191 • ACR Convergence 2020
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Brittany Weber¹, Zeling He¹, Sicong Huang¹, Daniel H. Solomon², Elena Massarotti¹, Charlotte Golnik¹, Thany Seyok¹, Seth Brownmiller¹, Laurel Martell¹, Leann Barrett¹, Courtney Bibbo¹, Marcy Bolster³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Concord, MA
Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
Abstract Number: 1207 • ACR Convergence 2020
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial
DaeHyun Yoo¹, Rene Westhovens², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, NooRi Han⁹ and YooBin Jung⁹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: In the analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical…
Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Esteban Rubio Romero¹, Alejandro Muñoz Jiménez², Rosalia Martinez Perez³ and Lara Mendez Diaz⁴, ¹VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, ²H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ³Virgen del Rocío University Hospital, seville, Spain, ⁴Virgen del Rocío Hospital, sevilla, Spain
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
Abstract Number: 1245 • ACR Convergence 2020
Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients
Sara McCoy¹ and Christie Bartels², ¹University of Wisconsin, Madison, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of…
Abstract Number: 1466 • ACR Convergence 2020
Multimorbidity in Rheumatoid Arthritis, Psoriatic Arthritis, Gout, and Osteoarthritis Within the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rheumatic and musculoskeletal diseases (RMDs) often predispose the development of other chronic conditions, resulting in multimorbidity. While multimorbidity is increasingly being recognized and examined…
Abstract Number: 1548 • ACR Convergence 2020
Blood Pressure, BMI and Sex Affect Optical Spectral Transmission Imaging Measurements of the Hands
Annelies Blanken¹, Conny van der Laken² and Mike Nurmohamed³, ¹Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Optical spectral transmission imaging (OST) is a new imaging method designed to measure inflammation in the hands of rheumatoid arthritis (RA) patients. The device…
Abstract Number: 1696 • ACR Convergence 2020
Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative
Stephen Bender¹, Michael Weinblatt² and Daniel Duch¹, ¹FACTORx, Cherry Hill, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medical claims data have been used since 2008 to measure the implementation of the diagnostic and referral strategies resulting from participation in RAPID® CME…
Abstract Number: 1726 • ACR Convergence 2020
Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
Abstract Number: 1743 • ACR Convergence 2020
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
Tariq Chukir¹, Susan Goodman², Haley Tornberg³, Huong Do⁴, Charlene Thomas⁵, Alana Sigmund³, Peter Sculco⁶, Bella Mehta⁶, Linda Russell⁶, Mark Figgie² and Emily Stein⁷, ¹Weill Cornell Medicine and New York Presbyterian Hospital, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown. Ideal GC dosing prevents perioperative…
Abstract Number: 1760 • ACR Convergence 2020
The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
Masaru Yoshimura¹, Yuichiro Fujieda², Michihito Kono², Masaru Kato², Kenji Oku², Olga Amengual² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
Abstract Number: 1964 • ACR Convergence 2020
Engaging Patients in the Development of a Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis
Sarah Hopkins Gillespie¹, Liana Fraenkel², Lisa Suter³, Gabriela Schmajuk⁴, Patricia Katz⁵, Alex Limanni⁶ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ³Yale School of Medicine, New Haven, CT, ⁴University of California, San Francisco, Atherton, CA, ⁵University of California, San Francisco, Novato, CA, ⁶n/a, Dallas, TX
Background/Purpose: The ACR Quality of Care committee is working to develop a quality measure to reflect functional assessment in rheumatoid arthritis (RA). One proposed approach…
Abstract Number: 2003 • ACR Convergence 2020
Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach
Elena Myasoedova¹, Arjun Athreya¹, Cynthia Crowson², Richard Weinshilboum¹, Liewei Wang¹ and Eric Matteson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Methotrexate (MTX) is the most common anchor drug for rheumatoid arthritis (RA), but the risk of missing the opportunity for early effective treatment with alternative medications…
Abstract Number: 0022 • ACR Convergence 2020
Association Between Changes in Pain Sensitization and Changes in Disease Activity After 12 Weeks of Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Andrew Heisler¹, Jing Song², Lutfiyya Muhammad³, Alyssa Wohlfahrt⁴, Wendy Marder⁵, Marcy Bolster⁶, Clifton Bingham III⁷, Daniel Clauw⁸, Dorothy Dunlop⁹, Tuhina Neogi¹⁰ and Yvonne Lee³, ¹Northwestern University Feinberg School of Medicine, Oak Park, IL, ²Northwestern University, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Brigham and Womans Hospital, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Massachusetts General Hospital, Concord, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸Michigan Medicine, Ann Arbor, MI, ⁹Northwestern University, New Haven, CT, ¹⁰Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have abnormalities in central nervous system regulation of pain, leading to enhanced pain sensitivity at joint sites (peripheral sensitization)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].